The rates of delayed nausea and vomiting by moderately emetogenic chemotherapy in patients with previous experience of acute emesis are usually quite high. This is a pilot study aiming to evaluate the safety of a new antiemetic schedule to prevent delayed emesis in this subset of patients.
During 5 consecutive cycles of moderately emetogenic chemotherapy, we evaluated 50 patients (15 males) who experienced acute emesis in the first cycle of treatment. The regimen for prevention of delayed emesis consisted of daily tropisetron (5 mg orally from d 2 to d 6 of each chemotherapeutic cycle) associated to ACTH-Depot (1 mg intramuscularly 24 and 68 h after the initiation of chemotherapy).
In 77% of chemotherapy cycles, there was a total elimination of nausea and vomiting, whereas in the remaining 23% of cycles, there was a major response defined as ≤ 2 vomiting episodes per cycle or nausea grade 1 according to the WHO. The efficacy of the antiemetic regimen persisted during the entire treatment program without the appearance of toxic effects.
The proposed antiemetic regimen is highly active in preventing delayed nausea and vomiting episodes in patients receiving moderately emetogenic chemotherapy. Moreover, no toxic effects were observed. These promising results require confirmation by a randomized trial.
ACTH-Depot plus tropisetron delayed nausea and vomiting moderately emetogenic chemotherapy pilot study
This is a preview of subscription content, log in to check access.
Kris, M.G., Roila, F., De Mulder, P.H., et al. (1998). Delayed emesis following anticancer chemotherapy. Support Care Cancer6(3):228–232.PubMedCrossRefGoogle Scholar
Ballatori, E., Roila, F., De Angelis, V., et al. (1997). Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts’ opinions. Multinational Association of Supportive Care in Cancer. Support Care Cancer5(4):269–273.PubMedCrossRefGoogle Scholar
The Italian Group for Antiemetic Research. (1997). Delayed emesis induced by moderately emetogenic chemotherapy: do we need to treat all patients? Ann. Oncol.8(6):561–567.CrossRefGoogle Scholar
Yalcin, S., Tekuzman, G., Baltali, E., et al. (1999). Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy: a randomized study. Am. J. Clin. Oncol.22(1):94–96.PubMedCrossRefGoogle Scholar
Campora, E., Giudici, S., Merlini, I., et al. (1994). Ondansetron and dexamethasone versus standard combination antiemetic therapy: a randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance at subsequent courses. Am. J. Clin. Oncol.: Cancer Clin. Trials17(6):522–526.Google Scholar
Pater, J.L., Lofters, W.S., Zee, B., et al. (1997). The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in the patients receiving moderately emetogenic chemotherapy. Ann. Oncol.8(2):181–185.PubMedCrossRefGoogle Scholar
Lofters, W.S., Pater, J.L., Zee, B., et al. (1997). Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J. Clin. Oncol.15(8):2966–2973.PubMedGoogle Scholar
Ioannidis, J.P., Hesketh, P.J., and Lau, J. (2000). Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J. Clin. Oncol.18(19):3409–3422.PubMedGoogle Scholar
Perez, E.A. (1999). 5-HT3 antiemetic therapy for patients with breast cancer. Breast Cancer Res. Treat.57(2):207–214.PubMedCrossRefGoogle Scholar
Antiemetic Subcommission of the Multinational Association of Supportive Care in Cancer (MASCC). (1998). Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Ann. Oncol.9(8):811–819.CrossRefGoogle Scholar
Gregory, R.E. and Ettinger, D.S. (1998). 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs55(2):173–189.PubMedCrossRefGoogle Scholar
Kaizer, L., Warr, D., Hoskins, P., et al. (1994). Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.12(5):1050–1057.PubMedGoogle Scholar
Koo, W.H. and Ang, P.T. (1996). Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann. Oncol.7(1):71–74.PubMedGoogle Scholar
The Italian Group for Antiemetic Research. (1995). Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N. Engl. J. Med.332(1):1–5.CrossRefGoogle Scholar
The Italian Group for Antiemetic Research. (2000). Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N. Engl. J. Med.342(21):1554–1559.CrossRefGoogle Scholar
Colbert, N., Izrael, V., Lotz, J.P., et al. (1983). Adrenocorticotropic hormone in the prevention of cisplatininduced nausea and vomiting. J. Clin. Oncol.1(10):635–639.PubMedGoogle Scholar
Passalacqua, R., Cocconi, G., Bella, M., et al. (1992). Double-blind, randomized trial for the control of delayed emesis in patients receiving cisplatin: Comparison of placebo vs adrenocorticotropic hormone (ACTH). Ann. Oncol.3(6):481–485.PubMedGoogle Scholar
Passalacqua, R., Cocconi, G., Caminiti, C., et al. (1997). Double-blind, multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cis-platin in adult patients with cancer. J. Clin. Oncol.15(6):2467–2473.PubMedGoogle Scholar
Karim, F., Roerig, S.C. and Saphier, D. (1996). Role of 5-hydroxytryptamine3 (5-HT3) antagonists in the prevention of emesis caused by anticancer therapy. Biochem. Pharmacol.52(5):685–685.PubMedCrossRefGoogle Scholar